Products Eculizumab is commercially available as a concentrate for the preparation of an infusion solution (Soliris). It was approved in many countries in January 2010. Structure and Properties Eculizumab is a monoclonal antibody produced by recombinant DNA technology in NSO cell lines. It is composed of two heavy and two light chains of amino acids … Eculizumab
Products The first therapeutic monoclonal antibody was approved in 1986. Muromonab-CD3 (Orthoclone OKT3) binds to the CD3 receptor on T cells and has been used in transplantation medicine. Numerous drugs containing antibodies are now available. A selection of active substances can be found at the end of this article. These are expensive drugs. For example, … Monoclonal Antibodies
Products Ravulizumab was approved in the United States in 2018, in the EU in 2019, and in many countries in 2020 as a concentrate for the preparation of an infusion solution (Ultomiris). Structure and properties Ravulizumab is an IgG2/4K monoclonal antibody produced by biotechnological methods. Effects Ravulizumab (ATC L04AA43) binds to complement protein C5, inhibiting … Ravulizumab
Symptoms Infection with enterohemorrhagic EHEC manifests as mild, watery to severe, and bloody diarrhea (hemorrhagic colitis). Other possible symptoms include nausea, vomiting, colicky abdominal pain and mild fever. The disease can lead to life-threatening complications, in particular to the hemolytic uremic syndrome HUS. This manifests itself in acute kidney failure, a drop in blood platelets … EHEC
